Ubs Group Ag Atara Biotherapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$0.44 - $1.22 $1.58 Million - $4.38 Million
-3,586,760 Reduced 97.12%
106,465 $73,000
Q4 2023

Feb 09, 2024
BUY
$0.23 - $1.74 $835,988 - $6.32 Million
3,634,733 Added 6214.07%
3,693,225 $1.88 Million
Q3 2023

Nov 09, 2023
BUY
$1.41 - $2.31 $10,034 - $16,440
7,117 Added 13.85%
58,492 $86,000
Q2 2023

Aug 11, 2023
SELL
$1.5 - $3.04 $424,818 - $860,964
-283,212 Reduced 84.65%
51,375 $82,000
Q1 2023

May 12, 2023
SELL
$2.8 - $5.46 $57,915 - $112,934
-20,684 Reduced 5.82%
334,587 $970,000
Q4 2022

Feb 08, 2023
BUY
$2.85 - $5.18 $767,952 - $1.4 Million
269,457 Added 314.0%
355,271 $1.17 Million
Q3 2022

Nov 10, 2022
BUY
$2.85 - $8.73 $128,238 - $392,815
44,996 Added 110.24%
85,814 $325,000
Q2 2022

Aug 10, 2022
SELL
$4.69 - $9.84 $977,700 - $2.05 Million
-208,465 Reduced 83.63%
40,818 $318,000
Q1 2022

May 16, 2022
BUY
$8.44 - $16.89 $31,135 - $62,307
3,689 Added 1.5%
249,283 $2.32 Million
Q4 2021

Feb 14, 2022
BUY
$14.7 - $19.89 $1.62 Million - $2.19 Million
110,274 Added 81.49%
245,594 $3.87 Million
Q3 2021

Nov 15, 2021
BUY
$11.99 - $17.9 $1.24 Million - $1.85 Million
103,517 Added 325.49%
135,320 $2.42 Million
Q2 2021

Aug 13, 2021
SELL
$12.89 - $16.58 $913,823 - $1.18 Million
-70,894 Reduced 69.03%
31,803 $494,000
Q1 2021

May 12, 2021
BUY
$14.0 - $20.72 $1.39 Million - $2.06 Million
99,396 Added 3011.09%
102,697 $1.47 Million
Q4 2020

Feb 11, 2021
SELL
$12.67 - $26.23 $6,765 - $14,006
-534 Reduced 13.92%
3,301 $65,000
Q3 2020

Nov 12, 2020
SELL
$11.92 - $15.87 $13,600 - $18,107
-1,141 Reduced 22.93%
3,835 $49,000
Q2 2020

Jul 31, 2020
SELL
$7.53 - $14.93 $37,514 - $74,381
-4,982 Reduced 50.03%
4,976 $72,000
Q1 2020

May 01, 2020
SELL
$5.69 - $17.78 $157,897 - $493,395
-27,750 Reduced 73.59%
9,958 $85,000
Q4 2019

Feb 14, 2020
SELL
$10.89 - $16.79 $68,193 - $105,138
-6,262 Reduced 14.24%
37,708 $621,000
Q3 2019

Nov 14, 2019
BUY
$12.03 - $19.94 $486,938 - $807,111
40,477 Added 1158.8%
43,970 $621,000
Q2 2019

Aug 14, 2019
BUY
$19.05 - $41.04 $35,109 - $75,636
1,843 Added 111.7%
3,493 $70,000
Q1 2019

May 14, 2019
SELL
$28.4 - $41.74 $18,857 - $27,715
-664 Reduced 28.69%
1,650 $66,000
Q4 2018

Feb 14, 2019
SELL
$30.9 - $42.97 $496,872 - $690,957
-16,080 Reduced 87.42%
2,314 $80,000
Q3 2018

Nov 14, 2018
BUY
$35.05 - $43.5 $615,968 - $764,469
17,574 Added 2143.17%
18,394 $760,000
Q2 2018

Aug 14, 2018
SELL
$35.15 - $51.45 $3.59 Million - $5.26 Million
-102,154 Reduced 99.2%
820 $30,000
Q1 2018

May 15, 2018
BUY
$18.0 - $48.35 $1.83 Million - $4.92 Million
101,698 Added 7970.06%
102,974 $4.02 Million
Q4 2017

Feb 14, 2018
BUY
$13.2 - $18.1 $2,838 - $3,891
215 Added 20.26%
1,276 $23,000
Q3 2017

Nov 14, 2017
BUY
$13.25 - $17.05 $13,793 - $17,749
1,041 Added 5205.0%
1,061 $17,000
Q2 2017

Aug 14, 2017
BUY
N/A
3 Added 17.65%
20 $0
Q1 2017

Nov 14, 2017
BUY
N/A
17
17 $0

Others Institutions Holding ATRA

# of Institutions
7
Shares Held
2.89M
Call Options Held
0
Put Options Held
0
View Full List

About Atara Biotherapeutics, Inc.

ATRA Quotes by TradingView
  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.25B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email